Fondevila C G, Meschengieser S, Blanco A, Peñalva L, Lazzari M A
Department of Hemostasis and Thrombosis, Instituto de Investigaciones Hematologicas Mariano R. Castex Buenos Aires, Argentina.
Thromb Res. 1989 Oct 1;56(1):29-36. doi: 10.1016/0049-3848(89)90005-4.
Apart from teratogenic phenomena and the potential risk of maternal or neonatal peripartum haemorrhage, the use of oral anticoagulants during pregnancy poses an additional hazard: the risk of transferring some anticoagulant activity to the nursing infant through breast milk. We analysed the coagulation status of seven full term breast-fed neonates whose mothers were under chronic anticoagulant therapy with acenocoumarine as thromboembolic prophylaxis following cardiac valve replacement. Prothrombin Times (PT) observed in neonates were significantly higher than the corresponding maternal values. Data were subsequently compared with those obtained from a control group comprising forty-two full term neonates nursed by non-anticoagulated mothers: coagulation profiles again showed no signs of any noticeable antivitamin K effect. Our results indicate that mothers given acenocoumarine at therapeutic doses may safely breast-feed their infants: anticoagulant activity in breast milk seems to be negligible as assessed by neonates PT.
除了致畸现象以及孕产妇或新生儿围产期出血的潜在风险外,孕期使用口服抗凝剂还存在另一个危害:通过母乳将一些抗凝活性传递给哺乳婴儿的风险。我们分析了7名足月母乳喂养新生儿的凝血状态,这些新生儿的母亲在心脏瓣膜置换术后接受醋硝香豆素慢性抗凝治疗以预防血栓栓塞。在新生儿中观察到的凝血酶原时间(PT)显著高于相应的母亲值。随后将数据与从由未接受抗凝治疗的母亲哺乳的42名足月新生儿组成的对照组获得的数据进行比较:凝血谱再次显示没有任何明显的抗维生素K效应的迹象。我们的结果表明,以治疗剂量服用醋硝香豆素的母亲可以安全地母乳喂养她们的婴儿:通过新生儿PT评估,母乳中的抗凝活性似乎可以忽略不计。